Core Viewpoint - The Hong Kong Stock Exchange welcomed four companies, including Impression Dahongpao Co., Ltd., Huashan Biotechnology (Qingdao) Co., Ltd., Mingki Hospital Group Co., Ltd., and Nanhua Futures Co., Ltd., to list simultaneously, showcasing the growing interest in the market [1] Group 1: Company Listings - Impression Dahongpao issued 36.1 million shares at an offering price of HKD 3.6 per share, raising approximately HKD 130 million, which will be used for upgrading its signature performance and expanding its business influence [1] - Huashan Biotechnology offered around 17.65 million shares at an issue price of HKD 38.2 per share, raising about HKD 670 million, aimed at supporting the clinical development and commercialization of its products [1] Group 2: Role of Huafu International - Huafu International acted as the joint bookrunner and lead underwriter for the successful issuance of Impression Dahongpao and Huashan Biotechnology, highlighting its cross-border service capabilities and professional execution as a Chinese securities firm in Hong Kong [1]
四企同日登陆港交所 华福国际助力两家成功发行
Zhong Guo Jin Rong Xin Xi Wang·2025-12-22 11:53